• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Ascensia, Senseonics partner with Nurse Practitioner Group on CGM insertion options

November 3, 2022 By Sean Whooley

Senseonics Eversense E3 Ascensia Diabetes Care
The Eversense E3 system. [Image from Ascensia/Senseonics]
Senseonics (NYSE:SENS) and Ascensia Diabetes Care launched a collaboration with the Nurse Practitioner Group (NPG) today.

NPG offers multidisciplinary health services and medical staffing solutions. The collaboration aims to broaden access to the Eversense E3 continuous glucose monitor (CGM) system. Senseonics developed Eversense E3 and Ascensia distributes the system as the company’s partner.

The collaboration offers convenient at-home and in-office insertion options for diabetes patients. NPG recently completed the first patient insertion of the six-month Eversense E3 sensor in Florida. It plans to expand the initiative to other key markets across the U.S. in the coming months.

Under the agreement, NPG providers may perform Eversense procedures in specified geographies for which they hold certification. It intends to offer services for patients with prescriptions for Eversense. Senseonics plans to assist NPG as it sets up its procedure capabilities.

Expanding options

“This partnership will expand options for existing and new Eversense users by making additional providers available for at-home or in-office device insertions,” said Tim Goodnow, president and CEO of Senseonics. “As Ascensia continues to drive Eversense E3 uptake in the U.S., we are excited to partner with the innovative team at NPG to make it more convenient to begin or continue receiving the benefits of this next-generation CGM.”

Senseonics, Ascensia and NPG all view the collaboration as a scalable solution. They hope for the expansion of access to Eversense E3 and the enhancing of the patient experience. Senseonics, Ascensia and NPG aim to streamline the Eversense workflow for healthcare providers who elect to not perform insertions themselves. This broadens the range of clinicians prescribing Eversense.

“The Nurse Practitioner Group is dedicated to providing quality healthcare to the diverse communities we serve through innovative, cost-effective strategies and this partnership aligns with our commitment of providing outstanding service and remarkable results,” said Stacey Santiago, president and CEO of NPG. “Dedicated members of our skilled staff will be trained and certified on the Eversense E3 CGM system insertion and removal procedures and credentialed to bill regionally. We are excited to offer Eversense users a convenient, professional solution for their twice-a-year insertions.”

About Eversense E3

Eversense E3 received FDA approval in February. Ascensia Diabetes Care, Senseonics’ global commercial partner, launched the system in the U.S. on April 4. The first U.S. patient received the E3 implantation that same week. Eversense E3 is Senseonics’ next-generation continuous glucose monitor (CGM) system. Eversense E3 lasts for up to six months (180 days). This doubles the wear time of its previous-generation CGM.

The system picked up CE mark approval in June. Europe already had a 180-day Senseonics CGM system available (Eversense XL). However, the next-generation Eversense E3 has a number of improvements over the XL. Those include reduced calibrations and enhanced survivability. Additionally, it offers non-adjunctive use, meaning fingersticks aren’t necessary for dosing decisions. Ascensia completed the European launch of E3 last month.

“Expanding and expediting access to this long-term, fully implantable CGM system is Ascensia’s number one priority and so we are thrilled to announce this initiative,” said Rob Schumm, president of Ascensia Diabetes Care. “Not only will more and more people with diabetes have access to Eversense CGM, but also the opportunity to have the insertion and removal procedures done in their homes or a nearby clinic. This added convenience is possible thanks to this collaboration with NPG.”

Filed Under: Business/Financial News, Diabetes, Drug-Device Combinations, Featured, Patient Monitoring, Technology Tagged With: Ascensia Diabetes Care, Eversense, Senseonics

IN CASE YOU MISSED IT

  • Medtronic enrolls first patient in study for Onyx liquid embolic system
  • BD issues voluntary recall on certain Alaris infusion pump modules
  • Sequel Med Tech expects full twiist launch in the fall
  • Insulet hires new chief HR officer from J&J
  • Breakthrough T1D, Mattel debut Barbie doll with type 1 diabetes

About Sean Whooley

Sean Whooley is an associate editor who mainly produces work for MassDevice, Medical Design & Outsourcing and Drug Delivery Business News. He received a bachelor's degree in multiplatform journalism from the University of Maryland, College Park. You can connect with him on LinkedIn or email him at swhooley@wtwhmedia.com.

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS